Athenex receives clearance to import potassium chloride injection concentrate
Athenex announced that the United States Food and Drug Administration has granted clearance for Athenex Pharmaceutical Division to import Potassium Chloride Injection Concentrate in response to a national drug shortage of that product. This FDA clearance allows APD to import Potassium Chloride Injection Concentrate on a temporary basis or for the duration of the shortage.Jeffrey Yordon, Athenex's COO and President of Athenex's Pharmaceutical Division, stated, "Potassium Chloride is currently on the drug shortage list of the FDA. We are happy to help provide a solution to the current shortage as we remain focused on developing novel therapies for the treatment of cancer." The importation of Potassium Chloride Injection began in August, 2018 and is currently helping supply the US market demand.